Back to mobile site

Stifel Reiterates Buy Rating on IGM Biosciences (IGMS)

October 1, 2024 6:55 AM EDT Send to a Friend
Stifel analyst Stephen Willey reiterated a Buy rating and $25.00 price target on IGM Biosciences (NASDAQ: IGMS).The analyst commented: "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login